Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIBE2: Upfront FOLFOXIRI + Bevacizumab vs Sequential Doublets in mCRC
NCT02339116Phase 3Unknown
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Feb 2015
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, irinotecan and bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Progression Free Survival 2. Status: unknown.
02
Drugs
fluorouraciloxaliplatinirinotecanbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02339116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339116.